Which has stronger valuation and earnings, BVS or SMTI?

Bioventus has higher revenue and earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $568.09M 1.25 $22.73M $0.41 20.76 Sanara MedTech $103.12M 1.85 -$37.56M -$3.77 N/A

Does the media favor BVS or SMTI?

In the previous week, Bioventus and Bioventus both had 4 articles in the media. Sanara MedTech's average media sentiment score of 1.19 beat Bioventus' score of 1.00 indicating that Sanara MedTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sanara MedTech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SSII or SMTI?

In the previous week, Sanara MedTech had 2 more articles in the media than SS Innovations International. MarketBeat recorded 4 mentions for Sanara MedTech and 2 mentions for SS Innovations International. Sanara MedTech's average media sentiment score of 1.19 beat SS Innovations International's score of 1.16 indicating that Sanara MedTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SS Innovations International 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sanara MedTech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CBLL or SMTI more profitable?

Sanara MedTech has a net margin of -31.23% compared to CeriBell's net margin of -63.51%. Sanara MedTech's return on equity of -3.19% beat CeriBell's return on equity. Company Net Margins Return on Equity Return on Assets CeriBell -63.51% -38.19% -30.92% Sanara MedTech -31.23% -3.19% -0.56%

Does the media favor CBLL or SMTI?

In the previous week, CeriBell had 1 more articles in the media than Sanara MedTech. MarketBeat recorded 5 mentions for CeriBell and 4 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 1.19 beat CeriBell's score of 0.56 indicating that Sanara MedTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sanara MedTech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, SIBN or SMTI?

SiBone has higher revenue and earnings than Sanara MedTech. SiBone is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $200.93M 3.40 -$18.90M -$0.39 N/A Sanara MedTech $103.12M 1.85 -$37.56M -$3.77 N/A

Is SIBN or SMTI more profitable?

SiBone has a net margin of -8.10% compared to Sanara MedTech's net margin of -31.23%. Sanara MedTech's return on equity of -3.19% beat SiBone's return on equity. Company Net Margins Return on Equity Return on Assets SiBone -8.10% -9.56% -7.06% Sanara MedTech -31.23% -3.19% -0.56%

Does the media favor SIBN or SMTI?

In the previous week, Sanara MedTech had 1 more articles in the media than SiBone. MarketBeat recorded 4 mentions for Sanara MedTech and 3 mentions for SiBone. Sanara MedTech's average media sentiment score of 1.19 beat SiBone's score of 0.60 indicating that Sanara MedTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SiBone 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sanara MedTech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BBNX or SMTI?

In the previous week, Beta Bionics had 2 more articles in the media than Sanara MedTech. MarketBeat recorded 6 mentions for Beta Bionics and 4 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 1.19 beat Beta Bionics' score of 0.22 indicating that Sanara MedTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Sanara MedTech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Sanara MedTech (SMTI) Competitors

$20.81 -0.69 (-3.21%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$21.52 +0.72 (+3.44%)

As of 06/12/2026 04:29 PM Eastern

Compare

SMTI vs. BVS, SSII, CBLL, SIBN, and BBNX

Should you buy Sanara MedTech stock or one of its competitors? MarketBeat compares Sanara MedTech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sanara MedTech include Bioventus (BVS), SS Innovations International (SSII), CeriBell (CBLL), SiBone (SIBN), and Beta Bionics (BBNX). These companies are all part of the "medical equipment" industry.

How does Sanara MedTech compare to Bioventus?

Bioventus (NASDAQ:BVS) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical equipment companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

Bioventus has higher revenue and earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09M	1.25	$22.73M	$0.41	20.76
Sanara MedTech	$103.12M	1.85	-$37.56M	-$3.77	N/A

Bioventus currently has a consensus price target of $14.00, indicating a potential upside of 64.51%. Sanara MedTech has a consensus price target of $34.00, indicating a potential upside of 63.38%. Given Bioventus' stronger consensus rating and higher probable upside, equities analysts plainly believe Bioventus is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Sanara MedTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Bioventus has a net margin of 4.94% compared to Sanara MedTech's net margin of -31.23%. Bioventus' return on equity of 29.97% beat Sanara MedTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	4.94%	29.97%	9.52%
Sanara MedTech	-31.23%	-3.19%	-0.56%

62.9% of Bioventus shares are owned by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are owned by institutional investors. 33.0% of Bioventus shares are owned by company insiders. Comparatively, 42.0% of Sanara MedTech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Bioventus has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market.

In the previous week, Bioventus and Bioventus both had 4 articles in the media. Sanara MedTech's average media sentiment score of 1.19 beat Bioventus' score of 1.00 indicating that Sanara MedTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanara MedTech	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Bioventus beats Sanara MedTech on 12 of the 16 factors compared between the two stocks.

How does Sanara MedTech compare to SS Innovations International?

SS Innovations International (NASDAQ:SSII) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

SS Innovations International has a beta of -1.89, suggesting that its share price is 289% less volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market.

8.1% of Sanara MedTech shares are owned by institutional investors. 42.0% of Sanara MedTech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

SS Innovations International has a net margin of -20.69% compared to Sanara MedTech's net margin of -31.23%. Sanara MedTech's return on equity of -3.19% beat SS Innovations International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SS Innovations International	-20.69%	-23.00%	-13.18%
Sanara MedTech	-31.23%	-3.19%	-0.56%

SS Innovations International has higher earnings, but lower revenue than Sanara MedTech. SS Innovations International is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SS Innovations International	$42.49M	15.83	-$12.13M	-$0.05	N/A
Sanara MedTech	$103.12M	1.85	-$37.56M	-$3.77	N/A

SS Innovations International presently has a consensus target price of $7.00, indicating a potential upside of 108.33%. Sanara MedTech has a consensus target price of $34.00, indicating a potential upside of 63.38%. Given SS Innovations International's higher possible upside, equities research analysts clearly believe SS Innovations International is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SS Innovations International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sanara MedTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Sanara MedTech had 2 more articles in the media than SS Innovations International. MarketBeat recorded 4 mentions for Sanara MedTech and 2 mentions for SS Innovations International. Sanara MedTech's average media sentiment score of 1.19 beat SS Innovations International's score of 1.16 indicating that Sanara MedTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SS Innovations International	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanara MedTech	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sanara MedTech beats SS Innovations International on 11 of the 16 factors compared between the two stocks.

How does Sanara MedTech compare to CeriBell?

CeriBell (NASDAQ:CBLL) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

Sanara MedTech has a net margin of -31.23% compared to CeriBell's net margin of -63.51%. Sanara MedTech's return on equity of -3.19% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
Sanara MedTech	-31.23%	-3.19%	-0.56%

Sanara MedTech has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$89.06M	7.87	-$53.41M	-$1.63	N/A
Sanara MedTech	$103.12M	1.85	-$37.56M	-$3.77	N/A

CeriBell has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market.

In the previous week, CeriBell had 1 more articles in the media than Sanara MedTech. MarketBeat recorded 5 mentions for CeriBell and 4 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 1.19 beat CeriBell's score of 0.56 indicating that Sanara MedTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanara MedTech	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CeriBell currently has a consensus price target of $22.20, indicating a potential upside of 20.19%. Sanara MedTech has a consensus price target of $34.00, indicating a potential upside of 63.38%. Given Sanara MedTech's higher probable upside, analysts plainly believe Sanara MedTech is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Sanara MedTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

8.1% of Sanara MedTech shares are held by institutional investors. 20.1% of CeriBell shares are held by insiders. Comparatively, 42.0% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Sanara MedTech beats CeriBell on 11 of the 17 factors compared between the two stocks.

How does Sanara MedTech compare to SiBone?

SiBone (NASDAQ:SIBN) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

SiBone currently has a consensus target price of $23.00, indicating a potential upside of 49.16%. Sanara MedTech has a consensus target price of $34.00, indicating a potential upside of 63.38%. Given Sanara MedTech's higher probable upside, analysts plainly believe Sanara MedTech is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Sanara MedTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Sanara MedTech had 1 more articles in the media than SiBone. MarketBeat recorded 4 mentions for Sanara MedTech and 3 mentions for SiBone. Sanara MedTech's average media sentiment score of 1.19 beat SiBone's score of 0.60 indicating that Sanara MedTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanara MedTech	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SiBone has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market.

SiBone has a net margin of -8.10% compared to Sanara MedTech's net margin of -31.23%. Sanara MedTech's return on equity of -3.19% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
Sanara MedTech	-31.23%	-3.19%	-0.56%

98.1% of SiBone shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 3.9% of SiBone shares are held by company insiders. Comparatively, 42.0% of Sanara MedTech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

SiBone has higher revenue and earnings than Sanara MedTech. SiBone is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	3.40	-$18.90M	-$0.39	N/A
Sanara MedTech	$103.12M	1.85	-$37.56M	-$3.77	N/A

Summary

SiBone and Sanara MedTech tied by winning 8 of the 16 factors compared between the two stocks.

How does Sanara MedTech compare to Beta Bionics?

Beta Bionics (NASDAQ:BBNX) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Beta Bionics has a beta of 3.4, meaning that its stock price is 240% more volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market.

Sanara MedTech has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	6.46	-$73.20M	-$1.51	N/A
Sanara MedTech	$103.12M	1.85	-$37.56M	-$3.77	N/A

In the previous week, Beta Bionics had 2 more articles in the media than Sanara MedTech. MarketBeat recorded 6 mentions for Beta Bionics and 4 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 1.19 beat Beta Bionics' score of 0.22 indicating that Sanara MedTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Sanara MedTech	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

8.1% of Sanara MedTech shares are held by institutional investors. 5.3% of Beta Bionics shares are held by insiders. Comparatively, 42.0% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Sanara MedTech has a net margin of -31.23% compared to Beta Bionics' net margin of -60.27%. Sanara MedTech's return on equity of -3.19% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-60.27%	-23.00%	-20.55%
Sanara MedTech	-31.23%	-3.19%	-0.56%

Beta Bionics presently has a consensus price target of $19.70, indicating a potential upside of 35.58%. Sanara MedTech has a consensus price target of $34.00, indicating a potential upside of 63.38%. Given Sanara MedTech's higher possible upside, analysts clearly believe Sanara MedTech is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Sanara MedTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Sanara MedTech beats Beta Bionics on 10 of the 17 factors compared between the two stocks.

Get Sanara MedTech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SMTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SMTI vs. The Competition

Export

Metric	Sanara MedTech	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$190.70M	$8.47B	$6.74B	$12.07B
Dividend Yield	N/A	2.50%	2.67%	5.67%
P/E Ratio	-5.52	15.64	24.21	24.42
Price / Sales	1.85	7.06	512.04	109.94
Price / Cash	35.00	17.44	27.48	37.92
Price / Book	31.06	3.62	10.66	6.83
Net Income	-$37.56M	$224.06M	$3.57B	$337.67M
7 Day Performance	-7.26%	-1.34%	0.84%	2.68%
1 Month Performance	-3.84%	2.10%	-0.34%	1.56%
1 Year Performance	-27.77%	-0.88%	25.40%	30.59%

Sanara MedTech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SMTI Sanara MedTech	2.1114 of 5 stars	$20.81 -3.2%	$34.00 +63.4%	-27.8%	$190.70M	$103.12M	N/A	60	Analyst Upgrade
BVS Bioventus	4.4627 of 5 stars	$9.15 -0.6%	$14.00 +53.1%	N/A	$763.56M	$568.09M	22.29	1,200	Positive News
SSII SS Innovations International	2.9162 of 5 stars	$3.64 +2.1%	$7.00 +92.6%	-5.1%	$727.47M	$42.49M	N/A	4	News Coverage Positive News
CBLL CeriBell	2.3804 of 5 stars	$18.41 -0.5%	$22.20 +20.6%	+6.9%	$696.20M	$89.06M	N/A	N/A	News Coverage Insider Trade
SIBN SiBone	2.3141 of 5 stars	$15.65 +0.8%	$23.00 +47.0%	-11.5%	$693.37M	$200.93M	N/A	350

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SMTI) was last updated on 6/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sanara MedTech (SMTI) Competitors

SMTI vs. BVS, SSII, CBLL, SIBN, and BBNX

How does Sanara MedTech compare to Bioventus?

Summary

How does Sanara MedTech compare to SS Innovations International?

Summary

How does Sanara MedTech compare to CeriBell?

Summary

How does Sanara MedTech compare to SiBone?

Summary

How does Sanara MedTech compare to Beta Bionics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMTI vs. The Competition

Sanara MedTech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sanara MedTech (SMTI) Competitors

SMTI vs. BVS, SSII, CBLL, SIBN, and BBNX

How does Sanara MedTech compare to Bioventus?

Which has stronger valuation and earnings, BVS or SMTI?

Do analysts prefer BVS or SMTI?

Is BVS or SMTI more profitable?

Do institutionals and insiders have more ownership in BVS or SMTI?

Which has more volatility and risk, BVS or SMTI?

Does the media favor BVS or SMTI?

Summary

How does Sanara MedTech compare to SS Innovations International?

Which has more risk & volatility, SSII or SMTI?

Do institutionals & insiders have more ownership in SSII or SMTI?

Is SSII or SMTI more profitable?

Which has better earnings & valuation, SSII or SMTI?

Do analysts prefer SSII or SMTI?

Does the media favor SSII or SMTI?

Summary

How does Sanara MedTech compare to CeriBell?

Is CBLL or SMTI more profitable?

Which has preferable earnings & valuation, CBLL or SMTI?

Which has more volatility & risk, CBLL or SMTI?

Does the media favor CBLL or SMTI?

Do analysts recommend CBLL or SMTI?

Do insiders and institutionals believe in CBLL or SMTI?

Summary

How does Sanara MedTech compare to SiBone?

Do analysts recommend SIBN or SMTI?

Does the media favor SIBN or SMTI?

Which has more volatility and risk, SIBN or SMTI?

Is SIBN or SMTI more profitable?

Do institutionals & insiders believe in SIBN or SMTI?

Which has stronger valuation & earnings, SIBN or SMTI?

Summary

How does Sanara MedTech compare to Beta Bionics?

Which has more risk & volatility, BBNX or SMTI?

Which has better earnings and valuation, BBNX or SMTI?

Does the media favor BBNX or SMTI?

Do institutionals and insiders believe in BBNX or SMTI?

Is BBNX or SMTI more profitable?

Do analysts recommend BBNX or SMTI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMTI vs. The Competition

Sanara MedTech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools